Performance of LFSPRO TP53 germline carrier risk predictions compared to standard genetic counseling practice on prospectively collected probands.

Jessica L CorredorElissa B Dodd-EatonJacynda Woodman-RossAshley WoodsonNam H NguyenGang PengSierra GreenAngelica M GutierrezBanu K ArunWenyi Wang

Published in: medRxiv : the preprint server for health sciences (2024)

LFSPRO showed improved sensitivity and specificity compared to Chompret criteria and GCs report a positive experience with LFSPRO. LFSPRO can be used to increase access to genetic testing for patients at risk for LFS and could help healthcare providers give more direct risk assessments regarding LFS testing and management for patients.

Keyphrases

healthcare
end stage renal disease
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
gene expression
dna methylation
smoking cessation
antiretroviral therapy